Gliclada

Gliclada

gliclazide

Manufacturer:

KRKA

Distributor:

Uni Drug
Concise Prescribing Info
Contents
Gliclazide
Indications/Uses
Type 2 diabetes in association w/ dietary measures & physical exercise when these measures alone are inadequate.
Dosage/Direction for Use
Initially 30 mg once daily, may be increased to 60, 90 or 120 mg daily if blood glucose is inadequately controlled. Max dose: 120 mg daily. Patient at risk of hypoglycaemia 30 mg once daily.
Administration
Should be taken with food.
Contraindications
Hypersensitivity to gliclazide, other sulphonylureas or sulphonamides. Insulin-dependent diabetes; diabetic pre-coma & coma, diabetic ketoacidosis; severe renal or hepatic insufficiency. Concomitant use w/ miconazole. Pregnancy & lactation.
Special Precautions
Increased risk of hypoglycaemia during low caloric diets, following prolonged/strenuous exercise, alcohol intake or in concomitant use w/ hypoglycaemic agents & sulphonylureas. Thyroid disorders, hypopituitarism & adrenal insufficiency. G6PD-deficiency. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. May affect the ability to drive & use machines. Renal & hepatic insufficiency. Childn.
Adverse Reactions
Hypoglycemia. Viral infection; rhinitis, bronchitis, pharyngitis, upper resp infection, coughing; back pain, arthralgia, arthrosis; inflicted injury; headache, asthenia; HTN, angina pectoris; UTI; diarrhoea; dizziness; hyperglycemia.
Drug Interactions
Increased hypoglycaemic effect w/ miconazole, phenylbutazone, other antidiabetic agents (eg, insulins, acarbose, metformin, thiazolidinediones, dipeptidylpeptidase-4 inhibitors, GLP-1 receptor agonists), clofibrate, high-dose salicylates, chloramphenicol, β-blockers, fluconazole, ACE inhibitors (eg, captopril, enalapril), H2-receptor antagonists, MAOIs, sulphonamides, clarithromycin & NSAIDs. Increased hypoglycaemic reaction leading to hypoglycaemic coma w/ alcohol. Increased blood glucose levels w/ danazol, thiazide diuretics, chlorpromazine, glucocorticoids, ritodrine, salbutamol, terbutaline IV. Potentiated anticoagulation effect of anticoagulant therapy (eg, warfarin).
MIMS Class
ATC Classification
A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Presentation/Packing
Form
Gliclada MR tab 60 mg
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in